Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial performance with record-high gross and EBITDA margins, significant revenue growth, and a robust cash position. The Q&A highlights positive sentiment towards pricing strategies and surgeon adoption, though some guidance lacks specifics. Despite slightly lower MACI growth guidance for 2026, the overall outlook remains optimistic with ongoing expansion efforts and potential BARDA RFP opportunities. The positive financial metrics and strategic growth initiatives suggest a likely stock price increase in the short term.
Key Financial Performance
Fourth Quarter Total Revenue $92.9 million, a 23% increase year-over-year. This growth was driven by strong performance in MACI and Burn Care segments.
Full Year Total Revenue $276.3 million, above the high end of guidance. This represents significant growth driven by MACI and Burn Care performance.
MACI Fourth Quarter Revenue $84.1 million, a 23% increase year-over-year and 51% sequential growth from the third quarter. Growth attributed to strong fundamentals, including record MACI implants and surgeon participation.
Burn Care Fourth Quarter Revenue $8.8 million, above guidance. This includes $32.1 million of Epicel revenue and $4.7 million of NexoBrid revenue for the full year.
Gross Margin (Fourth Quarter) 79% of revenue, representing significant margin expansion due to strong revenue performance.
Adjusted EBITDA Margin (Fourth Quarter) 40% of revenue, the highest quarterly margin to date, driven by revenue growth and operational efficiency.
Full Year Gross Margin 74%, an increase of nearly 200 basis points year-over-year, despite incremental investments in new facilities and sales force expansion.
Full Year Adjusted EBITDA Margin 26%, an increase of over 300 basis points year-over-year, reflecting operational efficiency and revenue growth.
GAAP Net Income (Full Year) $16.5 million, a nearly 60% increase year-over-year, driven by profit growth outpacing revenue growth.
Operating Cash Flow (Full Year) $52 million, with $200 million in cash and investments at year-end, reflecting a $35 million increase in the second half of the year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MACI Revenue Growth: MACI achieved record revenue of $84.1 million in Q4 2025, a 23% increase year-over-year, and 51% sequential growth from Q3. Full-year MACI revenue grew 21% to $239.5 million.
MACI Arthro: MACI Arthro technique trained approximately 1,000 surgeons, leading to significant biopsy and implant growth. Early data suggests reduced postsurgical pain, improved range of motion, and faster recovery.
MACI Ankle Clinical Study: Phase III MACI Ankle MASCOT clinical study initiated in Q4 2025, targeting a $1 billion addressable market.
MACI OUS Expansion: Plans to launch MACI outside the U.S. in 2027, starting with the U.K. Submission to U.K. MHRA expected mid-2026.
Sales Force Expansion: Completed MACI sales force expansion, increasing reach and penetration. Investments in commercial analytics and best practices aim to enhance execution.
New Manufacturing Facility: Commercial manufacturing for MACI in a new facility to begin in 2026, supporting OUS expansion.
Strategic Imperatives for 2026: Focus on leveraging expanded sales force, driving growth in small cartilage defects with MACI Arthro, and advancing life cycle management initiatives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company plans to submit a marketing authorization application to the U.K. MHRA for MACI in 2026, which involves navigating regulatory approval processes. Any delays or issues in obtaining approval could impact the planned launch in the U.K. in 2027.
Supply chain disruptions: The company is initiating commercial manufacturing for MACI in a new facility this year. Any disruptions or delays in the manufacturing process could impact product availability and revenue growth.
Economic uncertainties: The company’s financial performance is tied to market conditions and economic factors, which could affect revenue growth and profitability.
Strategic execution risks: The company is expanding its MACI sales force and implementing new commercial initiatives. Failure to effectively execute these strategies could hinder revenue growth and market penetration.
Market competition: The company operates in a competitive market for cartilage repair and burn care products. Increased competition could impact market share and pricing.
Clinical trial risks: The Phase III MACI Ankle MASCOT clinical study represents a substantial growth opportunity. However, any delays or negative outcomes from the trial could impact future revenue and market expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections for 2026: The company expects total revenue of approximately $316 million to $326 million for 2026. MACI revenue is projected to be approximately $280 million to $286 million, while Burn Care revenue is expected to range from $36 million to $40 million.
Quarterly Revenue Growth: For the first quarter of 2026, the company anticipates exceeding 20% total revenue growth, with MACI revenue projected at $54 million to $55 million and Burn Care revenue at $9 million to $10 million.
Gross Margin and Adjusted EBITDA Margin: The company expects a gross margin of approximately 75% and an adjusted EBITDA margin of approximately 27% for the full year 2026. For the first quarter, gross margin is expected to be around 70% and adjusted EBITDA margin approximately 10%.
MACI Sales Force Expansion Impact: The expanded MACI sales force is expected to drive deeper penetration and increased utilization within the current surgeon base. Sales rep productivity is anticipated to return to 2025 levels by 2027.
MACI Arthro Growth: The company aims to leverage MACI Arthro to drive growth in smaller cartilage defects, particularly on the femoral condyles. Early data suggests improved patient outcomes, including reduced postsurgical pain and faster recovery times.
MACI Ankle MASCOT Clinical Study: The Phase III MACI Ankle MASCOT clinical study has been initiated, targeting a potential addressable market of over $1 billion. This could expand the company's presence in the orthopedics market.
MACI OUS Expansion: The company plans to initiate commercial manufacturing for MACI in a new facility in 2026, with a potential launch in the U.K. in 2027. A marketing authorization application is expected to be submitted to the U.K. MHRA in mid-2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the company view the mix of price versus volume for MACI growth in 2025 and 2026?
A:The company sees pricing as a key growth driver, with over 95% of commercial cases approved for prior authorization. In 2025, growth was volume-driven in the second half, though both price and volume contributed. For 2026, pricing will remain part of the growth algorithm.
Q:What is the ratio of new doctor growth versus existing customer base for Arthro adoption?
A:About two-thirds of trained surgeons come from existing MACI users, and one-third are new or previously non-adopting surgeons. Trained surgeons show increased biopsy and growth rates, with Arthro cases leading to even higher growth and conversion rates.
Q:Why does the 2026 guidance for MACI growth imply slightly lower growth than the 20% mentioned in the 3Q '25 earnings call?
A:The guidance reflects prudence and discipline, with no material changes since the last call. The company ended 2025 stronger than expected, and the guidance assumes similar year-over-year incremental growth. The midpoint of the range aligns with last year's growth.
Q:What is the strategy and expectation for the sales force expansion?
A:The company expanded its sales force by 30% in Q4 2025 to support higher volumes and momentum. The new footprint increases reach and penetration among surgeons. The company expects rep productivity to return to previous levels by 2027.
Q:What are the expectations for free cash flow in 2026?
A:The company did not provide specific guidance but indicated that adjusted EBITDA is a good proxy for operating cash flow. CapEx is expected to remain in the low single-digit millions.
Q:What is the outlook for MACI growth in 2026, considering the larger sales force and conversion rates?
A:The company expects a balanced view for MACI growth, with no specific inflection from the new sales force baked into the guidance. Conversion rates for MACI Arthro-trained surgeons who performed cases are higher, and the company sees opportunities for outperformance.
Q:What is the progress on NexoBrid adoption and dormant Epicel accounts?
A:The company continues to reactivate dormant Epicel accounts and sees progress in NexoBrid adoption. Over 70 of 90 target accounts have placed orders for NexoBrid, and the focus is on moving accounts to consistent usage.
Q:When will the MACI Arthro 2.0 instruments be launched, and what improvements are expected?
A:The company is gathering feedback for enhancements to make MACI Arthro a simpler, less invasive procedure. The new instruments are expected to launch in 2027 at the earliest.
Q:What is the expected gross margin for 2026, and what factors contribute to it?
A:The company guides to a 75% gross margin for 2026, up from 74% in 2025. Incremental costs from operating multiple facilities contribute to the margin. Long-term, the company aims for high 70s gross margins by the end of the decade.
Q:What is the plan for MACI's ex-U.S. expansion, particularly in the U.K.?
A:The company plans to commercialize MACI directly in the U.K., leveraging an expedited approval pathway and concentrated call points in a dozen centers of excellence. No large commercial footprint is required.
Q:What is the status of the BARDA RFP, and what revenue impact is expected?
A:The BARDA RFP includes strategic stockpiling, additional indications, and a room temperature stable formulation. The company is optimistic about securing the award in 2026, but specific revenue impacts are not disclosed yet.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue impacts for the BARDA RFP and did not disclose detailed free cash flow guidance for 2026. Additionally, they did not specify the exact improvements for MACI Arthro 2.0 instruments or the precise revenue contribution from the sales force expansion.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ankle MASCOT
Ankle indication
Ankle study
MACI Ankle
MACI United
MACI class
MACI compound
MACI expansion
MACI foundation
MACI momentum
MACI payors
MACI profile
MACI quality
MACI segment
MASCOT study
MHRA middle
Nick result
Officer Chief
Relations sir
States MACI
States approach
Today Vice
UK
United States
approval
authorization
cartilage
case series
excellence
facility MACI
foundation place
imperative
objective
patient MACI
patient outcome
reimbursement
segment MACI
surgeon case
value
volume segment
year MACI
VCEL Transcript
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary and Q&A reveal strong financial performance, optimistic guidance, and strategic initiatives like MACI Arthro and international expansion. The Q&A highlights positive sentiment from analysts, with no significant competitive threats and strong growth drivers. The company's expanded sales force and BARDA award further bolster the outlook. Despite some unclear management responses, the overall sentiment is positive, suggesting a stock price increase in the 2% to 8% range.
Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reflects strong financial performance with record-high gross and EBITDA margins, significant revenue growth, and a robust cash position. The Q&A highlights positive sentiment towards pricing strategies and surgeon adoption, though some guidance lacks specifics. Despite slightly lower MACI growth guidance for 2026, the overall outlook remains optimistic with ongoing expansion efforts and potential BARDA RFP opportunities. The positive financial metrics and strategic growth initiatives suggest a likely stock price increase in the short term.
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Vericel Corporation (VCEL) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance, with record high operating cash flow and free cash flow, along with positive trends in MACI Arthro demand and surgeon adoption. The Q&A session reveals positive analyst sentiment, with no significant insurance challenges reported. The company's MACI sales force expansion and expected profitability improvements further support a positive outlook. However, cautious guidance for Q4 and lack of specific 2026 projections slightly temper enthusiasm. Overall, the sentiment is positive, with potential for a stock price increase in the 2% to 8% range.
VCEL Slides
Vericel Q1 2026 slides: 30% revenue growth drives guidance raise2026-05-07
Vericel Q4 2025 slides: record margins offset by 2026 guidance2026-02-26
Vericel Q2 2025 slides: MACI drives 21% revenue growth, margins expand2025-07-31
Vericel Q1 2025 slides: record revenue offset by widening losses, raises guidance2025-05-08
VCEL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
